4.4 Article

Different fever definitions and the rate of fever and neutropenia diagnosed in children with cancer: A retrospective two-center cohort study

Journal

PEDIATRIC BLOOD & CANCER
Volume 60, Issue 5, Pages 799-805

Publisher

WILEY
DOI: 10.1002/pbc.24380

Keywords

chemotherapy; fever definition; fever in neutropenia; infection; pediatric oncology

Ask authors/readers for more resources

Background The definition of fever, and thus fever and neutropenia (FN), varies between different pediatric oncology centers. Higher temperature limit should reduce FN rates, but may increase rates of FN with complications by delaying therapy. This study determined if different fever definitions are associated with different FN rates. Procedure Two pediatric oncology centers had used three fever definitions in 20042011: ear temperature 38.5 degrees C persisting 2hours (low definition); axillary temperature 38.5 degrees C 2hours or 39.0 degrees C once (middle); and ear temperature 39.0 degrees C once (high). Clinical information was retrospectively extracted from charts. FN rates were compared using mixed Poisson regression. Results In 521 pediatric patients with cancer, 783 FN were recorded during 6,009 months cumulative chemotherapy exposure time (501 years; rate, 0.13/month [95% CI, 0.120.14]), 124 of them with bacteremia (16%; 0.021/month [0.0170.025]). In univariate analysis, the high versus low fever definition was associated with a lower FN rate (0.10/month [0.080.11] vs. 0.15/month [0.130.16]; rate ratio, 0.66 [0.450.97]; P=0.036), the middle definition was intermediate (0.13/month [0.110.15]). This difference was not confirmed in multivariate analysis (rate ratio, 0.94 [0.671.33]; P=0.74). The high versus low definition was not associated with an increased rate of FN with bacteremia (multivariate rate ratio, 1.39 [0.533.62]; P=0.50). Conclusion A higher fever definition was not associated with a lower FN rate, nor with an increased rate of FN with bacteremia. These may be false negative findings due to methodological limitations. These questions, with their potential impact on health-related quality of life, and on costs, need to be assessed in prospective studies. Pediatr Blood Cancer 2013; 60: 799805. (c) 2012 Wiley Periodicals, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available